Generics & Biosimilars | Association for Accessible Medicines
Access! 2020 - Missed the early-bird? Save $300 off full-pass registration when you register by March 27
  • ""
    Generic Savings by Condition: The Latest Data
    When patients and providers opt for generic and biosimilar alternatives instead of brand-name prescription and biologic medications, the savings really add up—for any condition being treated.
  • ""
    Just Released: AAM White Paper
    New report by AAM finds health plans in the Medicare program and the commercial market are delaying patient access to new lower-priced generic competitors. #DoesntAddUp
  • #DoesntAddUp
    If generic prescription drug prices are falling each year, why are consumer costs for prescription drugs rising?
  • ""
    Access! 2020 Keynote Speaker Announced
    Chris Wallace, respected veteran newsman and host of Fox News Sunday, will speak at Access! 2020. Join us to hear a unique perspective on the industry.
  • ""
    Give IPR the Green Light
    IPR (Inter Partes Review) works. It expedites the pathway for generic and biosimilar medicines to come to market and it rewards true innovation. It's time for Congress to take action to enhance the PTO's IPR authority.
  • ""
    New Analysis of the BLOCKING Act
    New report from Matrix Global Advisors finds the delay of just one generic medicine will increase prescription drug costs for patients by $1.7 billion.
  • ""
    The Case for Competition
    Now available: AAM's full 2019 Generic Drug & Biosimilars Access & Savings in the U.S. Report

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.